The interaction of diltiazem with lovastatin and pravastatin

Lovastatin is oxidized by cytochrome P4503A to active metabolites but pravastatin is active alone and is not metabolized by cytochrome P450. Diltiazem, a substrate and a potent inhibitor of cytochrome P4503A enzymes, is commonly coadministered with cholesterol‐lowering agents.

[1]  R. Branch,et al.  Polymorphic metabolism of mephenytoin in man: Pharmacokinetic interaction with a co‐regulated substrate, mephobarbital , 1986, Clinical pharmacology and therapeutics.

[2]  D. Abernethy,et al.  Diltiazem treatment impairs hepatic drug oxidation: Studies of antipyrine , 1986, Clinical pharmacology and therapeutics.

[3]  H. Pan,et al.  Effect of food on pravastatin pharmacokinetics and pharmacodynamics. , 1993, International journal of clinical pharmacology, therapy and toxicology.

[4]  P. Neuvonen,et al.  Diltiazem enhances the effects of triazolam by inhibiting its metabolism , 1996, Clinical pharmacology and therapeutics.

[5]  K. Renton.  Inhibition of hepatic microsomal drug metabolism by the calcium channel blockers diltiazem and verapamil. , 1985, Biochemical pharmacology.

[6]  C. Shear,et al.  Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. I. Efficacy in modifying plasma lipoproteins and adverse event profile in 8245 patients with moderate hypercholesterolemia. , 1991, Archives of internal medicine.

[7]  C. Blum,et al.  Comparison of properties of four inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. , 1994, The American journal of cardiology.

[8]  P. Neuvonen,et al.  Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid , 1996, Clinical pharmacology and therapeutics.

[9]  T. Montague,et al.  High-performance liquid chromatographic assay of diltiazem and six of its metabolites in plasma: application to a pharmacokinetic study in healthy volunteers. , 1989, Journal of pharmaceutical sciences.

[10]  H. Iwabuchi,et al.  Biotransformation of pravastatin sodium (I). Mechanisms of enzymic transformation and epimerization of an allylic hydroxy group of pravastatin sodium. , 1993, Biochemical and biophysical research communications.

[11]  R. Lees,et al.  Rhabdomyolysis from the coadministration of lovastatin and the antifungal agent itraconazole. , 1995, The New England journal of medicine.

[12]  P. Neuvonen,et al.  Effect of Diltiazem on Midazolam and Alfentanil Disposition in Patients Undergoing Coronary Artery Bypass Grafting , 1996, Anesthesiology.

[13]  U. Christians,et al.  Comparison of pravastatin and lovastatin in renal transplant patients receiving cyclosporine. , 1996, Transplantation proceedings.

[14]  J. Tobert.  Efficacy and long-term adverse effect pattern of lovastatin. , 1988, The American journal of cardiology.

[15]  D. Illingworth,et al.  Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin. , 1988, The New England journal of medicine.

[16]  Y. Horsmans,et al.  Effects of simvastatin and pravastatin on 6 beta-hydroxycortisol excretion, a potential marker of cytochrome P-450 3A. , 1993, Pharmacological research.

[17]  A. Y. Lu,et al.  Biotransformation of lovastatin--III. Effect of cimetidine and famotidine on in vitro metabolism of lovastatin by rat and human liver microsomes. , 1990, Biochemical pharmacology.

[18]  Jungnickel Pw,et al.  Pravastatin: a new drug for the treatment of hypercholesterolemia. , 1992 .

[19]  S. Singhvi,et al.  Biotransformation of pravastatin sodium in humans. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[20]  J. Backman,et al.  Dose of midazolam should be reduced during diltiazem and verapamil treatments. , 1994, British journal of clinical pharmacology.

[21]  P. Keown,et al.  Cyclosporin-erythromycin interaction in normal subjects. , 1987, British journal of clinical pharmacology.

[22]  P. Jungnickel,et al.  Pravastatin: a new drug for the treatment of hypercholesterolemia. , 1992, Clinical pharmacy.

[23]  T. Leemann,et al.  In vitro comparative inhibition profiles of major human drug metabolising cytochrome P450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors , 1996, European Journal of Clinical Pharmacology.

[24]  P. Maurel,et al.  Cyclosporin A drug interactions. Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[25]  S. Grundy,et al.  Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation. , 1988, The New England journal of medicine.

[26]  B. Matuszewski,et al.  Determination of the HMG-CoA reductase inhibitors simvastatin, lovastatin, and pravastatin in plasma by gas chromatography/chemical ionization mass spectrometry. , 1993, Biological mass spectrometry.

[27]  H. Pan,et al.  Comparative Pharmacokinetics and Pharmacodynamics of Pravastatin and Lovastatin , 1990, Journal of clinical pharmacology.

[28]  H. Pan,et al.  Pharmacokinetic interaction between propranolol and the HMG-CoA reductase inhibitors pravastatin and lovastatin. , 1991, British journal of clinical pharmacology.

[29]  A. Y. Lu,et al.  Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. , 1991, Archives of biochemistry and biophysics.

[30]  C. Shear,et al.  Expanded clinical evaluation of lovastatin (EXCEL) study results: IV. Additional perspectives on the tolerability of lovastatin. , 1991, The American journal of medicine.

[31]  L. Benet,et al.  Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P‐glycoprotein: Implications for drug delivery and activity in cancer chemotherapy , 1995, Molecular carcinogenesis.

[32]  P. Macfarlane,et al.  Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .

[33]  W. F. Hoffman,et al.  Biotransformation of lovastatin. I. Structure elucidation of in vitro and in vivo metabolites in the rat and mouse. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[34]  D. Spach,et al.  Rhabdomyolysis associated with lovastatin and erythromycin use. , 1991, The Western journal of medicine.

[35]  G. Klassen,et al.  Steady-state plasma concentrations of diltiazem and its metabolites in patients and healthy volunteers. , 1996, Therapeutic drug monitoring.

[36]  Scandinavian Simvastatin Survival Study Group.  Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) , 1994, The Lancet.

[37]  Sarah A. Spinier,et al.  Comparative Evaluation of the Safety and Efficacy of HMG-CoA Reductase Inhibitor Monotherapy in the Treatment of Primary Hypercholesterolemia , 1995, The Annals of pharmacotherapy.

[38]  F. Brunner‐Ferber,et al.  Comparative Pharmacokinetics of Lovastatin, Simvastatin and Pravastatin in Humans , 1992, Journal of clinical pharmacology.

[39]  J. Hoeg,et al.  3-Hydroxy-3-methylglutaryl--coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. , 1987, JAMA.

[40]  M. Delaforge,et al.  Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. , 1995, Biochemical pharmacology.

[41]  M. Dietel,et al.  Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by P-glycoprotein. , 1992, Biochemical pharmacology.

[42]  D. Wortham,et al.  Terfenadine-ketoconazole interaction. Pharmacokinetic and electrocardiographic consequences. , 1993, JAMA.

[43]  M. Arnold,et al.  Determination of pravastatin sodium and its major metabolites in human serum/plasma by capillary gas chromatography/negative ion chemical ionization mass spectrometry. , 1989, Biomedical & environmental mass spectrometry.

[44]  R. Platt,et al.  Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings? , 1995, The New England journal of medicine.

[45]  D. Hunninghake,et al.  Biotransformation of lovastatin. V. Species differences in in vivo metabolite profiles of mouse, rat, dog, and human. , 1993, Drug metabolism and disposition: the biological fate of chemicals.